To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. PCSK9 inhibitors enable high risk patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia to achieve Canadian guideline recommended lipid treatment targets. Only a minority of patients are able to benefit from this therapy. Some reasons include lack of affordability and patient reluctance to embrace a new treatment.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile